MedPath
HSA Product

SETROF TABLET 50MG

Product approved by Health Sciences Authority (SG)

Basic Information

SETROF TABLET 50MG

TABLET, FILM COATED

Regulatory Information

SIN14221P

September 5, 2012

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XN06AB06

Company Information

HOVID Bhd.

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Active Ingredients

Detailed Information

Contraindications

**CONTRAINDICATIONS** - Contraindicated in patients with a known hypersensitivity to sertraline. - Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated. - Concomitant use in patients taking pimozide is contraindicated.

Indication Information

**INDICATIONS** Sertraline is indicated for the treatment of: 1. symptoms of depression, including depression accompanied by symptoms of anxiety, in patients with or without a history of mania. Following satisfactory response, continuation with sertraline therapy is effective in preventing relapse of the initial episode of depression or recurrence of further depressive episodes. 2. obsessive compulsive disorder (OCD). Following initial response, sertraline has been associated with sustained efficacy, safety and tolerability in up to 2 years of treatment of OCD. 3. panic disorder, with or without agoraphobia. 4. post-traumatic stress disorder (PTSD). 5. social phobia (social anxiety disorder). 6. premenstrual dysphoric disorder (PMDD).

© Copyright 2025. All Rights Reserved by MedPath